LB Pharmaceuticals to present posters on Phase 2 NOVA trial of LB-102

LB Pharmaceuticals (LBRX) announced that three posters featuring new and previously reported analyses from its Phase 2 NOVA clinical trial of LB-102 in acute schizophrenia will be presented at the 38th European College of Neuropsychopharmacology Congress, taking place in Amsterdam, The Netherlands, from October 11-14, 2025. Among the presentations will be an analysis evaluating the effects of LB-102 on cognition in patients with acute schizophrenia. Cognition was included in the Phase 2 NOVA1 trial as an exploratory endpoint. Using a validated battery of cognitive tests, this post-hoc analysis demonstrated that after four weeks of treatment with LB-102, a robust, dose-dependent, and significant treatment effect size was identified in a completer population for all doses of LB-102 compared with placebo. The treatment effect size versus placebo was 0.26 at the 50 mg dose, 0.41 at the 75 mg dose and reached 0.66 at the 100 mg dose. The patient population included in this analysis was not enriched for severe cognitive impairment at baseline. Significant effect sizes of the magnitude reported in this trial provide early evidence that LB-102 may positively impact cognitive deficits-an area of significant unmet need not adequately addressed by existing antipsychotics. In addition to the cognitive findings, the Company will present two additional posters at the 38th ECNP Congress: an encore presentation of the primary efficacy and safety results from the NOVA1 trial, and a post-hoc analysis focused on the effects of LB-102 on negative symptoms in a subset of patients with prominent negative symptoms at baseline. Collectively, these analyses further reinforce LB-102’s balanced clinical profile, which is characterized by robust reduction in Positive and Negative Syndrome Scale scores, a generally favorable and potentially class-leading tolerability profile, and differentiated clinical activity across multiple symptom domains. We believe these findings support further investigation of LB-102’s potential to deliver comprehensive disease management in schizophrenia, beyond just positive symptom control.